Table of Contents Chapter 1 Overview of High Potency Active Pharmaceutical Ingredients (HPAPI) 1.1 Definition of High Potency Active Pharmaceutical Ingredients (HPAPI) in This Report 1.2 Commercial Types of High Potency Active Pharmaceutical Ingredients (HPAPI) 1.2.1 Synthetic 1.2.2 Biotech 1.3 Downstream Application of High Potency Active Pharmaceutical Ingredients (HPAPI) 1.3.1 Synthetic 1.3.2 Biotech Oncology 1.3.3 Hormonal 1.3.4 Glaucoma 1.3.5 Others 1.4 Development History of High Potency Active Pharmaceutical Ingredients (HPAPI) 1.5 Market Status and Trend of High Potency Active Pharmaceutical Ingredients (HPAPI) 2013-2023 1.5.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Status and Trend 2013-2023 1.5.2 Regional High Potency Active Pharmaceutical Ingredients (HPAPI) Market Status and Trend 2013-2023 Chapter 2 EMEA Market Status and Forecast by Regions 2.1 Market Status of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA 2013-2017 2.2 Consumption Market of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions 2.2.1 Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions 2.2.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions 2.3 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions 2.3.1 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Europe 2013-2017 2.3.2 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Middle East 2013-2017 2.3.3 Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) in Africa 2013-2017 2.4 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA 2018-2023 2.4.1 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA 2018-2023 2.4.2 Market Development Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) by Regions 2018-2023 Chapter 3 EMEA Market Status and Forecast by Types 3.1 Whole EMEA Market Status by Types 3.1.1 Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types 3.1.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types 3.2 EMEA Market Status by Types in Major Countries 3.2.1 Market Status by Types in Europe 3.2.2 Market Status by Types in Middle East 3.2.3 Market Status by Types in Africa 3.3 Market Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types Chapter 4 EMEA Market Status and Forecast by Downstream Industry 4.1 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Downstream Industry 4.2 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Major Countries 4.2.1 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Europe 4.2.2 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Middle East 4.2.3 Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Africa 4.3 Market Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Downstream Industry Chapter 5 Market Driving Factor Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) 5.1 EMEA Economy Situation and Trend Overview 5.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Downstream Industry Situation and Trend Overview Chapter 6 High Potency Active Pharmaceutical Ingredients (HPAPI) Market Competition Status by Major Players in EMEA 6.1 Sales Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Major Players 6.2 Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Major Players 6.3 Basic Information of High Potency Active Pharmaceutical Ingredients (HPAPI) by Major Players 6.3.1 Headquarters Location and Established Time of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players 6.3.2 Employees and Revenue Level of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 High Potency Active Pharmaceutical Ingredients (HPAPI) Major Manufacturers Introduction and Market Data 7.1 Eli Lilly and Company 7.1.1 Company profile 7.1.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.1.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Eli Lilly and Company 7.2 Novartis International AG 7.2.1 Company profile 7.2.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.2.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Novartis International AG 7.3 Bristol-Myers Squibb Company 7.3.1 Company profile 7.3.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.3.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company 7.4 Roche Diagnostics Limited 7.4.1 Company profile 7.4.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.4.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Roche Diagnostics Limited 7.5 Sanofi Aventis 7.5.1 Company profile 7.5.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.5.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sanofi Aventis 7.6 Hospira, Inc. 7.6.1 Company profile 7.6.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.6.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Hospira, Inc. 7.7 BASF AG 7.7.1 Company profile 7.7.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.7.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of BASF AG 7.8 Covidien Plc 7.8.1 Company profile 7.8.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.8.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Covidien Plc 7.9 Boehringer Ingelheim GmbH 7.9.1 Company profile 7.9.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.9.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH 7.10 Merck & Co., Inc. 7.10.1 Company profile 7.10.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.10.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. 7.11 Sigma Aldrich Corporation 7.11.1 Company profile 7.11.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.11.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sigma Aldrich Corporation 7.12 Bayer AG 7.12.1 Company profile 7.12.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.12.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bayer AG 7.13 Carbogen Amcis AG 7.13.1 Company profile 7.13.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.13.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Carbogen Amcis AG 7.14 Lonza 7.14.1 Company profile 7.14.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.14.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Lonza 7.15 Teva Pharmaceuticals Industries Ltd. 7.15.1 Company profile 7.15.2 Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product 7.15.3 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals Industries Ltd. Chapter 8 Upstream and Downstream Market Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) 8.1 Industry Chain of High Potency Active Pharmaceutical Ingredients (HPAPI) 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) 9.1 Cost Structure Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) 9.2 Raw Materials Cost Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) 9.3 Labor Cost Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) 9.4 Manufacturing Expenses Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) Chapter 10 Marketing Status Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI) 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Synthetic Table Advantage and Disadvantage of Biotech Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions 2013-2017 Table Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions 2013-2017 Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions 2018-2023 Table Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Regions 2018-2023 Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types 2013-2017 Table Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types 2013-2017 Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in Europe 2013-2017 Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in Middle East 2013-2017 Table Consumption Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Types in Africa 2013-2017 Table Consumption Volume Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types 2018-2023 Table Revenue Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Types 2018-2023 Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Downstream Industry 2013-2017 Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Europe 2013-2017 Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Middle East 2013-2017 Table Demand Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) by Downstream Industry in Africa 2013-2017 Table Demand Volume Forecast of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Downstream Industry 2018-2023 Table Sales Volume of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Major Players 2013-2017 Table Revenue of High Potency Active Pharmaceutical Ingredients (HPAPI) in EMEA by Major Players 2013-2017 Table Headquarters Location and Established Time of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players Table Employees and Revenue Level of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Players Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Eli Lilly and Company Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Eli Lilly and Company Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Eli Lilly and Company 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Novartis International AG Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Novartis International AG Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Novartis International AG 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Bristol-Myers Squibb Company Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Bristol-Myers Squibb Company Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Roche Diagnostics Limited Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Roche Diagnostics Limited Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Roche Diagnostics Limited 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Sanofi Aventis Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Sanofi Aventis Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sanofi Aventis 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Hospira, Inc. Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Hospira, Inc. Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Hospira, Inc. 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of BASF AG Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of BASF AG Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of BASF AG 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Covidien Plc Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Covidien Plc Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Covidien Plc 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Boehringer Ingelheim GmbH Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Boehringer Ingelheim GmbH Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Merck & Co., Inc. Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Merck & Co., Inc. Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Sigma Aldrich Corporation Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Sigma Aldrich Corporation Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Sigma Aldrich Corporation 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Bayer AG Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Bayer AG Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Bayer AG 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Carbogen Amcis AG Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Carbogen Amcis AG Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Carbogen Amcis AG 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Lonza Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Lonza Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Lonza 2013-2017 Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product One of Teva Pharmaceuticals Industries Ltd. Table Representative High Potency Active Pharmaceutical Ingredients (HPAPI) Product Two of Teva Pharmaceuticals Industries Ltd. Table High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals Industries Ltd. 2013-2017